Table 3 Medication treatment modalities by study cohort. The medication numbers do not match the respective patient cohort sizes due to an overlap of multiple medications applied in individual patients
Number of patients per cohort | “Early 2020” (n = 3,221) | “Late 2020” (n = 6,417) | Total (N = 9,638) |
|---|---|---|---|
Number of patients per medication | |||
Azithromycin | 2,063 (64.05%) | 3,039 (47.36%) | 5,102 (52.94%) |
Corticosteroids | 2,282 (70.85%) | 6,216 (96.87%) | 8,498 (88.17%) |
Hydroxychloroquine | 1,157 (35.92%) | 82 (1.28%) | 1,239 (12.86%) |
Remdesivir | 834 (25.89%) | 3,290 (51.27%) | 4,124 (42.79%) |
Tocilizumab | 549 (17.04%) | 251 (3.91%) | 800 (8.30%) |